Shots:

• RedHill regains exclusive WW rights for RHB-106 signed in 2014- encapsulated formulation for bowel preparation
• In 2014- RedHill signed a license agreement with Salix to commercialize RHB-106 in specific territories. RedHill received $7M up front and up to $5M in milestones- plus royalties
• RHB-106 is a flavorless- odorless- solid oral encapsulated formulation P-IIa candidate targeted for cleansing of the gastrointestinal tract prior to the performance of abdominal procedures and diagnostic tests

Click here to read full press release/ article | Ref: RedHill Biopharma | Image: Signbox